echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dongyang Sun declares PD-1 monoclonal antibody biosimilars

    Dongyang Sun declares PD-1 monoclonal antibody biosimilars

    • Last Update: 2021-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 3, the CDE official website showed that Dongyang Sunshine’s 3.
    3-type recombinant anti-PD-1 fully human monoclonal antibody injection was declared for clinical use
    .


    This is the second domestically reported PD-1 biosimilar drug, and it is presumed to be a nivolumab biosimilar drug


    Shandong Boan Biology was the first to declare PD-1 biosimilars in China
    .


    The nivolumab-like drug LY01015 was first submitted for clinical application in February 2021 and was approved for clinical use on May 6, and clinical trials have not yet started


    The internal volume of PD-1 is continuously increasing.


    According to the Insight database, in addition to the approved products, there are still 32 models under development; dual antibodies are the new hotspot in research and development.


    Domestic PD-1 pattern (Clinical Phase III project)

    From: Insight database

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.